Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.54, read 2026-11-03
Ethical does not pass the values gate
Price313.52 USD
Fair value303.95
Ethical score70.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation302.74+3.6% to today ✓Markdown gives way to Accumulation after a 7% rise in 4 weeks
2026-09-04Read Markdown281.72+11.3% to today Markup gives way to Markdown after a 10% rise in 9 weeks
2026-07-02Read Markup255.54+22.7% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ligand Pharmaceuticals Incorporated holds its Accumulation at $313.52. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-11-03
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$313.52
Valuation
32.29 trailing · 25.64 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.01
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.93%
Below 33%
Interest-bearing debt is just 28.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
12.62%
Below 33%
Cash held in interest-bearing accounts and securities is 12.6% of assets, under the one-third limit.
Pass
Receivables
15.03%
Below 49%
Money owed to the company is 15.0% of assets, under the 49% limit.
Pass
Revenue purity
5.09%
Below 5%
5.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ligand Pharmaceuticals clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 5% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LGND's ethical verdict changes
Today LGND does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades above our $303.95 fair value estimate, 33.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 3.1% above the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +10% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $303.95, with a range of $222.30 to $349.54, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech licensor offers strong margins yet no margin of safety
Picture a company that simply licenses drug formulas rather than running full clinical trials. Ligand does exactly that and posts a 56 percent profit margin with 14 percent revenue growth and 17 percent return on equity. Those numbers look solid on paper yet our fair value sits at 281.87 while the shares trade at 303.39, giving a negative margin of safety and a clear none rating on opportunity.
The business model keeps overhead low by partnering assets such as EVOMELA and KYPROLIS into approved treatments worldwide. Forward earnings sit at 26.3 times and ten analysts still carry a strong buy stance with a 310 median target. Ethical screening clears the name without issue, which removes one common reason to step aside.
Valuation risk remains the decisive factor here. A modest premium to fair value can quickly reverse in a sector where royalty streams face patent cliffs and partner concentration. The absence of any moat rating adds further uncertainty around durability. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LGND trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$303.53-0.9%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$306.40+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$306.40+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$306.40+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$306.40+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$306.40+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$306.40+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$306.40+0.9%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$303.53+0.3%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
